We use cookies to ensure that we give you the best experience on our website Learn more

My documents

Jan 18, 2019

34th BHS General Annual Meeting

MRD discrepancy during follow-up of p190 BCR-ABL1+ childhood B-ALL: diagnosis of a ‘CML-like’ ALL subgroup






Purpose A patient (M, 14 yr.) was diagnosed with B-ALL showing 92% lymphoid blasts and p190 BCR-ABL1 fusion transcript, and treated according to the EsphALL protocol with EORTC 58081+Glivec induction. Measurable residual disease (MRD) monitoring was performed by BCR-ABL1 qPCR, flow cytometry (FCM) for the detection of a leukemia-associated phenotype (LAIP) and a patient-tailored allele-specific oligonucleotide (ASO) qPCR. After six months, FCM and ASO-qPCR persistently showed negative MRD, in contrast to consistently high BCR-ABL1 copy number (CN) ratios (Fig.1). We here discuss the follow-up of a pediatric patient in an apparent state of remission with MRD discrepancy between BCR-ABL1 qPCR (positive) and ASO-qPCR/FCM (negative). Material and methods Molecular detection of the BCR-ABL1 fusion transcript was performed conform EAC guidelines. FCM detection of the LAIP CD38low/CD19+/CD10++/CD66c+/CD20- was performed on a FACSCanto II (BD) with instrument set-up and (pre-)analytical handlings according to EuroFlow guidelines. Two clonal targets (IGHV1-NL1*01-IGHJH6 and Vg8-Jg2.3) were defined as targets for ASO-qPCR set-up according to the Euro-MRD guidelines (sensitivity 10-4 and 10-5). Sorting was performed following bulk lysis and antibody staining (CD19/CD3/CD11b/CD14/CD33/CD45) on an Aria III sorter (BD). Results To investigate the biological basis of this discordancy, peripheral blood was examined 29 months post-diagnosis (BCR-ABL1/ABL1 CN ratio 4.94%) with sorting of different mature cell populations. The BCR-ABL1 fusion transcript was detected in neutrophils, monocytes, B-cells and T-cells with ratio’s 12.9%, 1.8%, 13.1% and 3.3%, respectively. This multilineage involvement implies that hematopoietic stem cells were most likely the cell of origin, as previously described by Hovorkova et al (Blood 2017), who defined a CML-like ALL subgroup that differs from typical ALL and CML. Conclusion The diagnosis of ‘CML-like’ BCR-ABL1+ ALL is suggested in case of MRD+/- discrepancy between BCR-ABL1 qPCR and ASO-qPCR/FCM, and may be confirmed by cell-sorting of the non-leukemic hematopoietic cells at remission.

Discover over 20,000 new abstracts, posters and presentations from leading academic conferences every month. Stay on top of the latest findings, methodologies and discussions happening in your research field around the world.



Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.